GlaxoSmithKline has enrolled the first patient in a Phase IIb clinical program with Theravance‘s compound 642444 (‘444), an investigational long-acting beta2 agonist (LABA), in patients with mild to moderate asthma. The collaboration now has two compounds in this phase of development in the Beyond Advair collaboration: ‘444, a GSK-discovered compound, and 159797 (‘797), a Theravance-discovered compound. The goal of this collaboration is to develop a once-a-day inhaled com...